Evidence map›Paper›PMID 36070252›Full record

ArticlePloS one2022

SILVI, an open-source pipeline for T-cell epitope selection.

Joana Pissarra, Franck Dorkeld, Etienne Loire, Vincent Bonhomme, Denis Sereno, Jean-Loup Lemesre, Philippe Holzmuller

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Joana PissarraUMR INTERTRYP, IRD, CIRAD, University of Montpellier (I-MUSE), Montpellier, France.ORCID 0000-0002-0506-8042
Franck DorkeldUMR CBGP, INRAE, CIRAD, IRD, Montpellier SupAgro, University of Montpellier (I-MUSE), Montpellier, France.
Etienne LoireUMR ASTRE, CIRAD, INRAE, University of Montpellier (I-MUSE), Montpellier, France.
Vincent BonhommeISEM, CNRS, EPHE, IRD, University of Montpellier (I-MUSE), Montpellier, France.
Denis SerenoUMR INTERTRYP, IRD, CIRAD, University of Montpellier (I-MUSE), Montpellier, France.ORCID 0000-0002-0034-9291
Jean-Loup LemesreUMR INTERTRYP, IRD, CIRAD, University of Montpellier (I-MUSE), Montpellier, France.
Philippe HolzmullerUMR ASTRE, CIRAD, INRAE, University of Montpellier (I-MUSE), Montpellier, France.
Centre de Coopération Internationale en Recherche Agronomique pour le Développement · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-throughput screening of available genomic data and identification of potential antigenic candidates have promoted the development of epitope-based vaccines and therapeutics. Several immunoinformatic tools are available to predict potential epitopes and other immunogenicity-related features, yet it is still challenging and time-consuming to compare and integrate results from different algorithms. We developed the R script SILVI (short for: from in silico to in vivo), to assist in the selection of the potentially most immunogenic T-cell epitopes from Human Leukocyte Antigen (HLA)-binding prediction data. SILVI merges and compares data from available HLA-binding prediction servers, and integrates additional relevant information of predicted epitopes, namely BLASTp alignments with host proteins and physical-chemical properties. The two default criteria applied by SILVI and additional filtering allow the fast selection of the most conserved, promiscuous, strong binding T-cell epitopes. Users may adapt the script at their discretion as it is written in open-source R language. To demonstrate the workflow and present selection options, SILVI was used to integrate HLA-binding prediction results of three example proteins, from viral, bacterial and parasitic microorganisms, containing validated epitopes included in the Immune Epitope Database (IEDB), plus the Human Papillomavirus (HPV) proteome. Applying different filters on predicted IC50, hydrophobicity and mismatches with host proteins allows to significantly reduce the epitope lists with favourable sensitivity and specificity to select immunogenic epitopes. We contemplate SILVI will assist T-cell epitope selections and can be continuously refined in a community-driven manner, helping the improvement and design of peptide-based vaccines or immunotherapies. SILVI development version is available at: github.com/JoanaPissarra/SILVI2020 and https://doi.org/10.5281/zenodo.6865909.

Indexed as

Epitopes, T-LymphocyteVaccinesAlgorithmsHumansLymphocyte ActivationProteinsEpitopes, T-LymphocyteProteinsVaccines

Identifiers

PMID36070252
PMCPMC9451077
OpenAlexW4294884133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.